Catalent | CTLT - Operating Profit


Catalent reported $-67M in Operating Profit for its fiscal quarter ending in September of 2024.



Operating Profit Change Date
Agilent USD 444M 45M Jun/2026
AstraZeneca USD 3.16B 3.95B Jun/2026
Bristol-Myers Squibb USD 299M 3.07B Jun/2026
Bruker USD 69.6M 59.4M Jun/2026
Centene USD -43.18B 45.04B Jun/2026
Charles River Laboratories USD 119.89M 9K Jun/2026
Cigna USD 2.76B 204M Mar/2026
Danaher USD 1.25B 118M Sep/2026
Dentsply International USD 84M 52M Jun/2026
Elevance Health USD 2.15B 149M Sep/2026
Eli Lilly USD 12.46B 2.68B Jun/2026
Glaxosmithkline GBP 2.29B 3.08M Mar/2026
Humana USD 1.36B 394M Jun/2026
Illumina USD 260M 21M Jun/2026
Intuitive Surgical USD 1.05B 69.9M Sep/2026
IQVIA Holdings USD 2.6B 2.03B Jun/2026
J&J USD 6.47B 1B Sep/2026
Laboratory Of America USD 456.7M 46.6M Jun/2026
Lonza CHF 673M 243M Jun/2025
McKesson USD 1.42B 415M Jun/2026
Merck EUR 1.1B 51M Jun/2026
Merck USD 840M 2.72B Jun/2026
Mettler Toledo International USD 287.55M 53.61M Jun/2026
Novartis USD 4.75B 515M Jun/2026
Pfizer USD 667M 4.32B Jun/2026
Quest Diagnostics USD 479M 20M Sep/2026
Repligen USD 21.13M 1.15M Jun/2026
Revvity USD 126.14M 43.36M Jun/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
Supernus Pharmaceuticals USD -21.04M 14.21M Jun/2026
Thermo Fisher Scientific USD 2.46B 277M Sep/2026
UnitedHealth USD 6.34B 1.65B Sep/2026
Veradigm USD -45.47M 70.47M Dec/2022
Waters USD -86M 234M Jun/2026
West Pharmaceutical Services USD 179.1M 2M Jun/2026